NNNN Anbio Biotechnology Annual reports only
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1982708 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY5.6%
TTM net income YoY169.9%
TTM EPS YoY162.5%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR-13.8%
Margins
Gross margin87.2%
Operating margin66.7%
Net margin74.1%
FCF margin—
EBITDA margin—
Returns
ROE27.0%
ROA26.0%
ROIC (approx.)41.5%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets0.3%
Debt / equity0.00x
Current ratio344.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.05x
Accruals ratio53.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $8.65M | $8.19M | $6.71M | $23.54M |
| Cost of revenue | $1.10M | $2.30M | $3.35M | $10.98M |
| Gross profit | $7.54M | $5.89M | $3.36M | $12.56M |
| R&D expense | $201,305 | $454,227 | $134,700 | $200,000 |
| SG&A expense | $1.57M | $3.44M | $1.27M | $2.17M |
| Operating income | $5.77M | $2.00M | $1.96M | $10.20M |
| Interest expense | — | — | — | $7,999 |
| Pretax income | $6.40M | $2.37M | $2.25M | $10.01M |
| Income tax | $0 | $0 | $0 | — |
| Net income | $6.40M | $2.37M | $2.25M | $10.01M |
| EPS (basic) | 0.15 | 0.06 | 0.10 | 100,112.00 |
| EPS (diluted) | 0.15 | 0.06 | 0.10 | 100,112.00 |
| Weighted avg. shares (diluted) | 43.67M | 42.29M | 21.44M | — |
| Balance sheet | ||||
| Cash & equivalents | $7.77M | $11.76M | $9.69M | $7.10M |
| Short-term investments | $4.13M | $0 | — | — |
| Receivables | $3.66M | $1.06M | $1.88M | — |
| Current assets | $30.24M | $18.53M | $15.75M | — |
| Total assets | $30.24M | $18.92M | $15.81M | — |
| Current liabilities | $87,836 | $1.73M | $993,060 | — |
| Total liabilities | $87,836 | $1.73M | $993,060 | — |
| Shareholders' equity | $30.16M | $17.19M | $14.82M | $12.55M |
| Cash flow statement | ||||
| Operating cash flow | -$6.74M | $2.08M | $898,367 | $4.45M |
| Investing cash flow | -$4.20M | $337,101 | $1.73M | -$1.53M |
| Financing cash flow | $6.95M | -$344,605 | -$42,835 | — |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.